Cholesteryl ester transfer protein in patients with coronary heart disease

European Journal of Clinical Investigation

Volumn 40, Issue 7, 2010, Pages 616-622

  Duwensee, Kristina ^a   Breitling, Lutz Philipp ^b   Tancevski, Ivan ^a   Rothenbacher, Dietrich ^b   Demetz, Egon ^a   Patsch, Josef R ^a   Ritsch, Andreas ^a   Eller, Philipp ^a   Brenner, Hermann ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Atherosclerosis; Coronary heart disease; Lipoproteins; Mortality; Risk factors

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; EFFECT SIZE; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 77953504477     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02313.x     Document Type: Article

References (36)

1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007 370: 1829 1839.
2. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990 323: 1234 1238.
3. Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007 48: 1263 1272.
4. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000 406: 203 207.
5. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999 19: 1105 1110.
6. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993 34: 1255 1274.
7. Zhao L, Jin W, Rader D, Packard C, Feuerstein G. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Biochem Pharmacol 2009 78: 315 325.
8. Koizumi J, Mabuchi H, Yoshimura A, Michishita I, Takeda M, Itoh H et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985 58: 175 186.
9. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004 350: 1505 1515.
10. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 356: 1620 1630.
11. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 356: 1304 1316.
12. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357: 2109 2122.
13. Olsson AG. Is high HDL cholesterol always good? Ann Med 2009 41: 11 8.
14. Rader DJ. Illuminating HDL-is it still a viable therapeutic target? N Engl J Med 2007 357: 2180 2183.
15. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography. Circulation 2010 121: 366 374.
16. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009 120: 2414 2420.
17. Twardella D, Loew M, Rothenbacher D, Stegmaier C, Ziegler H, Brenner H. The diagnosis of a smoking-related disease is a prominent trigger for smoking cessation in a retrospective cohort study. J Clin Epidemiol 2006 59: 82 9.
18. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006 26: 1586 1593.
19. Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 2006 166: 2455 2460.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al. The strengthening the reporting of observational sturdiest in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007 4: e296.
21. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010 40: 35 53.
22. Ritsch A, Auer B, Foger B, Schwarz S, Patsch JR. Polyclonal antibody-based immunoradiometric assay for quantification of cholesteryl ester transfer protein. J Lipid Res 1993 34: 673 679.
23. Ritsch A, Ebenbichler C, Naschberger E, Schgoer W, Stanzl U, Dietrich H et al. Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification. Clin Chem Lab Med 2004 42: 247 255.
24. Hosmer DW, Lemeshow S, Maye S. Applied Survival Analysis: Regression of Modeling of Time to Event Data.
25. SAS Institute. Statistical Analysis Software, Release 9.2.
26. Dallinga-Thie GM, Dullaart RP, van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007 18: 251 257.
27. Ikewaki K, Mabuchi H, Teramoto T, Yamada N, Oikawa S, Sasaki J et al. Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects. Metabolism 2003 52: 1564 1570.
28. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb 1991 11: 797 804.
29. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003 26: 1216 1223.
30. Jahangiri A, de Beer AC, Noffsinger V, Tannock LR, Ramaiah C, Webb NR et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009 29: 261 267.
31. Lakomy D, Rebe C, Sberna AL, Masson D, Gautier T, Chevriaux A et al. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. Arterioscler Thromb Vasc Biol 2009 29: 1923 1929.
32. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl J Med 1998 338: 86 93.
33. Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008 29: 2792 2799.
34. Boekholdt AM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women. Circulation 2004 110: 1418 1423.
35. Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol 2008 28: 1890 1891.
36. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008 51: 2199 2211.